Face- and eye-muscle research sheds new light on Duchenne muscular dystrophy

April 11, 2016

In a new study, a research team at Basel University Hospital in Switzerland investigates the biochemical and physiological characteristics of orbicularis oculi, a group of facial muscles that control the eyelids and are selectively spared or involved in different neuromuscular disorders. What they found also helps to explain why another set of muscles--the extraocular muscles that control the movement of the eye--are not affected by Duchenne muscular dystrophy, congenital muscular dystrophy, and aging.

The study, "Functional characterization of orbicularis oculi and extraocular muscles," by Marijana Sekulic-Jablanovic et al., will appear online April 11 ahead of print of the May issue of The Journal of General Physiology (JGP).

Using healthy human muscle cell cultures and differentiated human myotubes grown on glass coverslips, the team led by Susan Treves, PhD and Francesco Zorzato, MD, PhD, of the departments of Anaesthesia and Biomedicine at Basel University Hospital, examined the excitation-contraction coupling (ECC) process and calcium homeostasis in the orbicularis oculi, extraocular muscles, and a third muscle group--the quadriceps.

ECC is the process whereby an electrical signal is converted into a chemical signal leading to muscle contraction. They found that ECC machinery and calcium regulation of human orbicularis oculi are more similar to those of quadriceps than of extraocular muscles.

"Although gene expression in orbicularis oculi is quite different from that in quadriceps, the expression of proteins involved in the ECC process is similar in both cell types," the authors note.

The researchers also gained unique insight into the presence and absence of dystrophin, the protein located primarily in muscles used for movement, and utrophin, which shares both structural and functional similarities with dystrophin.

In patients with neuromuscular disorders, weakness is apparent in the orbicularis oculi. Although mitochondrial myopathies and myasthenia gravis often first target the orbicularis oculi and the extraocular muscles, this is not the case in Duchenne muscular dystrophy.

Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy in children and primarily targets boys, according to the Centers for Disease Control and Prevention, and it results in the loss of the ability to walk between ages 7 and 13 years, and death in the teens or 20s. DMD is caused by a defective gene for dystrophin.

In the study, the researchers found high levels of dystrophin and low levels of utrophin in the quadriceps. Orbicularis oculi and extraocular muscles, however, expressed low levels of dystrophin and high levels of utrophin.

"Our results concerning the expression of utrophin are interesting and most likely explain why ocular and facial muscles are spared in patients with Duchenne muscular dystrophy," the authors say.

The authors note that dystrophin and utrophin may share distinct binding partners since their subcellular distribution, at least in myotubes, is different. Dystrophin has a punctate membrane distribution, whereas utrophin has a patchy more filamentous distribution concentrated within specific subcellular domains. Also promising, dystrophin-deficient mdx mouse studies show that utrophin can functionally compensate in vivo for the lack of dystrophin.

"This supports current strategies aimed at modulating utrophin expression in the therapy for Duchenne muscular dystrophy," the authors conclude. "Taken together, these studies show that satellite cells derived from different muscles are primed and will follow the developmental characteristics of their muscle of origin, a property that can be exploited in laboratories devoted to tissue engineering."
Sekulic-Jablanovic, et al. 2016. J Gen. Physiol.http://dx.doi.org/10.1085/jgp.201511542

About The Journal of General Physiology

The Journal of General Physiology (JGP) is published by The Rockefeller University Press. All editorial decisions on manuscripts submitted are made by research-active scientists in conjunction with our in-house scientific editors. JGP provides free online access to many article types immediately, with complete archival content freely available online since the journal's inception. Authors retain copyright of their published works, and third parties may reuse the content for non-commercial purposes under a creative commons license. For more information, please visit jgp.org. Follow us on Twitter at @JGenPhysiol and @RockUPress.

Rockefeller University Press

Related Duchenne Muscular Dystrophy Articles from Brightsurf:

Genetic mutation could worsen heart function in Duchenne muscular dystrophy patients
DALLAS - Nov. 4, 2020 - A mutation in the gene that causes cystic fibrosis may accelerate heart function decline in those with Duchenne muscular dystrophy (DMD), a new study by UT Southwestern researchers suggests.

New Duchenne muscular dystrophy drug shows benefit in Duke trial
A new drug offers hope for young boys with the progressive neuromuscular disease Duchenne muscular dystrophy (DMD) by potentially offering an alternative to high-dose glucocorticoids that have significant side effects.

Scientists uncover a novel approach to treating Duchenne muscular dystrophy
Scientists at Sanford Burnham Prebys, Fondazione Santa Lucia IRCCS, and Università Cattolica del Sacro Cuore have shown that pharmacological (drug) correction of the content of extracellular vesicles released within dystrophic muscles can restore their ability to regenerate muscle and prevent muscle scarring.

Using CRISPR to find muscular dystrophy treatments
A study from Boston Children's Hospital used CRISPR-Cas9 to better understand facioscapulohumeral muscular dystrophy (FSHD) and explore potential treatments by systematically deleting every gene in the genome.

Releasing brakes: Potential new methods for Duchenne muscular dystrophy therapies
Testing of small molecules in mouse models for Duchenne muscular dystrophy shows promise for restoration of muscle structure and function.

Duchenne muscular dystrophy diagnosis improved by simple accelerometers
Testing for Duchenne muscular dystrophy can require specialized equipment, invasive procedures and high expense, but measuring changes in muscle function and identifying compensatory walking gait could lead to earlier detection.

Gene therapy for Duchenne muscular dystrophy safely preserves muscle function
A gene therapy being developed at Penn Medicine to treat Duchenne muscular dystrophy (DMD) successfully and safely stopped the severe muscle deterioration associated with the rare, genetic disease in both small and large animal models, according to a first-of-its-kind study from Penn Medicine researchers.

Cheaper drug just as effective protecting heart in duchenne muscular dystrophy
A new clinical trial conducted by Ohio State University found a cost-effective generic drug works just as well as a more expensive drug in preserving heart function in boys with Duchenne muscular dystrophy.

Researchers' discovery could lead to improved therapies for duchenne muscular dystrophy
Researchers found that the protein sarcospan can play a major role in combating heart failure in patients with Duchenne muscular dystrophy.

Duchenne muscular dystrophy prevalence increases, while incidence remains steady
In the first study of its kind involving Duchenne muscular dystrophy (DMD) in the US, researchers from the Deerfield Institute found that while the number of new cases has remained stable, there has been an uptick in prevalence -- largely attributed to enhanced treatments and longevity.

Read More: Duchenne Muscular Dystrophy News and Duchenne Muscular Dystrophy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.